R&D projects

The Siena Biotech Portfolio is centred on novel and precedented targets together with pathway or phenotypic approaches in two primary therapeutic areas, Neurodegeneration, in particular Alzheimer's disease and Huntington's disease and Oncology, with a focus on neuro oncology.
In each disease area we are building a robust pipeline of compounds which are optimised with an emphasis on using functional data in a disease-relevant context with close attention to appropriate physicochemical properties.  >>
    

Business Model

We integrate chemistry, pharmacology, ADMET and imaging technologies to fast track the advancement of hits to candidates for regulatory preclinical services. In Early Discovery, we can generate compound libraries and identify hits by in-silico modeling or high throughput screening and validate them through a combined approach including in-vitro and in-silico technologies. Lead Optimization is supported by a seamless integration of medicinal chemistry with ADME, toxicology, in-vitro pharmacology, and in-vivo models of safety and efficacy.  >>

nnnnn

Progetto di Formazione con Borsa di Studio
NUOVI FARMACI EPIGENETICI CONTRO IL CANCRO, LA NEURODEGENERAZIONE
E LE PATOLOGIE CARDIOVASCOLARI
 >>
Bando riaperto